Axsome Therapeutics Acquires Baergic Bio to Secure Global Rights to AZD7325

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Engrail Therapeutics Acquires NeuroCycle Therapeutics

February 2, 2021

Biotechnology

Engrail Therapeutics has acquired NeuroCycle Therapeutics, a small neuroscience company focused on sub-type selective GABA-A modulation. The acquisition expands Engrail's GABA-A portfolio and provides a platform to advance multiple assets toward clinical trials and further pipeline development.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

Alexion (AstraZeneca Rare Disease) Acquires LogicBio Therapeutics

November 16, 2022

Biotechnology

Alexion, AstraZeneca Rare Disease, has completed its acquisition of LogicBio Therapeutics, Inc. through a tender offer and merger, making LogicBio a wholly owned subsidiary. The deal is intended to accelerate Alexion's growth in genomic medicines by adding LogicBio's genomic medicine technology and rare disease R&D expertise; LogicBio's CEO Frederic Chereau will join Alexion as SVP, Strategy and Business Development.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.